Lupin enters in partnership agreement with China's Foncoo Pharma for high-quality and complex generic medicines

19 Jan 2022 , 11:44 AM

Lupin Ltd on Wednesday announced its partnership with Shenzhen Foncoo Pharmaceutical Co. Ltd. which reinforces its commitment to bringing high-quality generic and complex generic medicines to patients around the world. This partnership is in arrangement with China and enforces Lupin’s commitment to bring high-quality generic and complex generic medicines to patients around the world.

“Lupin continues to invest in key growth markets. With China’s growing dedication to affordable and accessible healthcare for all, Lupin is dedicated to serving the healthcare needs of the Chinese population by bringing forth high quality generic and complex generic products,” said Dr. Fabrice Egros, President — Growth Markets, Lupin.

He further added, “We are thrilled about our partnership with Foncoo and seek to further explore additional partnership opportunities in China to leverage our global portfolio including complex generics and specialty medicines.”

“Foncoo’s successful experiences on importing registration and marketing of the generic formulations and Lupin’s strong capability of making high-quality medicines make us perfect match to each other and our collaboration will have a bright future most likely. We expect that the successful launch of our first product in China will come smoothly and soon. We will continue to explore further opportunities to work with Lupin for providing more and more high-value and complex medicines to the Chinese physicians and patients,” said General Manager, Mr. Peng Yan, Foncoo.

Lupin enjoys leader position in the cardiovascular, respiratory segments and anti-diabetic, and has a significant presence in the anti-infective, gastro-intestinal (GI), women’s health, and central nervous system (CNS) areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions.